LAVA Therapeutics N.V. - Ordinary Shares (LVTX)
1.4400
+0.0300 (2.13%)
Lava Therapeutics N.V. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment
The company specializes in its unique platform technology aimed at harnessing the power of gamma delta T cells, a type of immune cell that plays a significant role in the body’s defense against tumors. By creating novel immune-oncology treatments, Lava Therapeutics strives to improve patient outcomes and provide more effective options for those battling various forms of cancer. Through rigorous research and development, the company seeks to advance its product pipeline and bring new therapies to market, aiming to address unmet medical needs in the oncology space.

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.
Via Benzinga · February 28, 2025

Via Benzinga · February 27, 2025

These stocks have an unusual volume in today's session
Via Chartmill · February 26, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · February 25, 2025

Via Benzinga · August 23, 2023

Via Benzinga · October 25, 2022

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · February 25, 2025

Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.
Via Chartmill · February 25, 2025

LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 20, 2024

LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 21, 2024

LVTX stock results show that LAVA Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 20, 2024

The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week.
Via Benzinga · January 26, 2024

Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!
Via InvestorPlace · January 26, 2024

U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The S&P 500 also rose, gaining, 0.26% to 4,881.28.
Via Benzinga · January 25, 2024

Shares of Humana Inc. (NYSEHUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Via Benzinga · January 25, 2024

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.33% to 37,932.33 while the NASDAQ rose 0.37% to 15,538.69. The S&P 500 also rose, gaining, 0.40% to 4,887.88.
Via Benzinga · January 25, 2024

LAVA Therapeutics collaborates with Merck on a clinical trial for anti-PD-1 therapy Keytruda in metastatic castration-resistant prostate cancer.
Via Benzinga · January 25, 2024

Gainers MultiMetaVerse Holdings Limited (NASDAQMMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group.
Via Benzinga · June 2, 2023

Gainers Better Choice Company Inc. (NASDAQBTTR) shares rose 37% to $0.4522 in pre-market trading. Better Choice said it has selected Re:Amaze to assist in customer retention and acquisition for its Halo Brand of dog and cat food.
Via Benzinga · June 2, 2023

It's time for a dive into the biggest pre-market stock movers for Friday as we check out the winners and losers this morning!
Via InvestorPlace · June 2, 2023

Gainers Crown ElectroKinetics Corp. (NASDAQCRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Via Benzinga · December 14, 2022

Gainers Vallon Pharmaceuticals, Inc. (NASDAQVLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio.
Via Benzinga · December 14, 2022

Upgrades
Via Benzinga · October 25, 2022

Piper Sandler raised Snap Inc. (NYSESNAP) price target from $11 to $12. Piper Sandler analyst Thomas Champion maintained the stock with a Neutral. Snap shares fell 1.4% to close at $10.18 on Monday.
Via Benzinga · September 27, 2022